Tuberculous pleurisy with effusion

Chih Jen Hsu, Kuan Jen Bai, I. Hsin Chiang, Ming Pin Wu, Tao Ping Lin, Sow Hsong Kuo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

To assess the clinical features of Taiwanese patients with tuberculous pleurisy and their response to treatment, we analyzed the records of patients treated for this condition from December 1990 through November 1995, at a regional 100-bed referral center for tuberculosis care. Diagnosis of tuberculous pleurisy was based on histologic evidence of caseating granulomatous inflammation in the pleural biopsy specimen, or evidence of mycobacteria in pleural fluid. Patients were also stratified on the basis of parenchymal involvement. Ninety-seven patients (79 men, 18 women) with a mean age of 47.5 (range, 15-90) years were included in the analysis. The two major symptoms were cough (69%) and shortness of breath (57%). Chest roentgenographs showed that the pleural effusion was unilateral in 88 (91%) patients, and small to moderate in amount in 74 (76%). Laboratory analysis of the pleural fluid showed moderate levels of glucose (4.6 mmol/L), with no significant difference between patients with and without parenchymal involvement. The levels of lactate dehydrogenase and triglycerides were significantly higher in patients with parenchymal involvement (172 vs 240.5 IU and 0.36 vs 0.45 mmol/L, respectively). In 85 of 93 patients (91%) with available data, lymphocytes were predominant in the differential count. All patients had received short-course chemotherapy for at least 6 months. After excluding the defaulters and patients receiving subsequent management in other hospitals, the overall rate of successful treatment was 97% (72/74). There was no significant difference in the treatment outcome between patients with parenchymal involvement and those without. None of the successfully treated patients had a relapse within a mean follow-up period of 31.7 ± 18.4 months. We conclude that current patients with tuberculous pleurisy in Taiwan are not young, and short-course chemotherapy with isoniazid, ethambutol, rifampicin, and pyrazinamide is an effective treatment. The presence of parenchymal tuberculous lesions does not appear to influence the treatment outcome.

Original languageEnglish
Pages (from-to)678-682
Number of pages5
JournalJournal of the Formosan Medical Association = Taiwan yi zhi
Volume98
Issue number10
Publication statusPublished - Oct 1999
Externally publishedYes

Fingerprint

Pleural Tuberculosis
Pyrazinamide
Drug Therapy
Ethambutol
Isoniazid
Pleural Effusion
Rifampin
Mycobacterium
Taiwan
L-Lactate Dehydrogenase
Cough
Dyspnea

Keywords

  • Parenchymal involvement
  • Treatment outcome
  • Tuberculous pleurisy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hsu, C. J., Bai, K. J., Chiang, I. H., Wu, M. P., Lin, T. P., & Kuo, S. H. (1999). Tuberculous pleurisy with effusion. Journal of the Formosan Medical Association = Taiwan yi zhi, 98(10), 678-682.

Tuberculous pleurisy with effusion. / Hsu, Chih Jen; Bai, Kuan Jen; Chiang, I. Hsin; Wu, Ming Pin; Lin, Tao Ping; Kuo, Sow Hsong.

In: Journal of the Formosan Medical Association = Taiwan yi zhi, Vol. 98, No. 10, 10.1999, p. 678-682.

Research output: Contribution to journalArticle

Hsu, CJ, Bai, KJ, Chiang, IH, Wu, MP, Lin, TP & Kuo, SH 1999, 'Tuberculous pleurisy with effusion', Journal of the Formosan Medical Association = Taiwan yi zhi, vol. 98, no. 10, pp. 678-682.
Hsu CJ, Bai KJ, Chiang IH, Wu MP, Lin TP, Kuo SH. Tuberculous pleurisy with effusion. Journal of the Formosan Medical Association = Taiwan yi zhi. 1999 Oct;98(10):678-682.
Hsu, Chih Jen ; Bai, Kuan Jen ; Chiang, I. Hsin ; Wu, Ming Pin ; Lin, Tao Ping ; Kuo, Sow Hsong. / Tuberculous pleurisy with effusion. In: Journal of the Formosan Medical Association = Taiwan yi zhi. 1999 ; Vol. 98, No. 10. pp. 678-682.
@article{bd8ea3a1fa1e4642a6ed8e13b7386ddd,
title = "Tuberculous pleurisy with effusion",
abstract = "To assess the clinical features of Taiwanese patients with tuberculous pleurisy and their response to treatment, we analyzed the records of patients treated for this condition from December 1990 through November 1995, at a regional 100-bed referral center for tuberculosis care. Diagnosis of tuberculous pleurisy was based on histologic evidence of caseating granulomatous inflammation in the pleural biopsy specimen, or evidence of mycobacteria in pleural fluid. Patients were also stratified on the basis of parenchymal involvement. Ninety-seven patients (79 men, 18 women) with a mean age of 47.5 (range, 15-90) years were included in the analysis. The two major symptoms were cough (69{\%}) and shortness of breath (57{\%}). Chest roentgenographs showed that the pleural effusion was unilateral in 88 (91{\%}) patients, and small to moderate in amount in 74 (76{\%}). Laboratory analysis of the pleural fluid showed moderate levels of glucose (4.6 mmol/L), with no significant difference between patients with and without parenchymal involvement. The levels of lactate dehydrogenase and triglycerides were significantly higher in patients with parenchymal involvement (172 vs 240.5 IU and 0.36 vs 0.45 mmol/L, respectively). In 85 of 93 patients (91{\%}) with available data, lymphocytes were predominant in the differential count. All patients had received short-course chemotherapy for at least 6 months. After excluding the defaulters and patients receiving subsequent management in other hospitals, the overall rate of successful treatment was 97{\%} (72/74). There was no significant difference in the treatment outcome between patients with parenchymal involvement and those without. None of the successfully treated patients had a relapse within a mean follow-up period of 31.7 ± 18.4 months. We conclude that current patients with tuberculous pleurisy in Taiwan are not young, and short-course chemotherapy with isoniazid, ethambutol, rifampicin, and pyrazinamide is an effective treatment. The presence of parenchymal tuberculous lesions does not appear to influence the treatment outcome.",
keywords = "Parenchymal involvement, Treatment outcome, Tuberculous pleurisy",
author = "Hsu, {Chih Jen} and Bai, {Kuan Jen} and Chiang, {I. Hsin} and Wu, {Ming Pin} and Lin, {Tao Ping} and Kuo, {Sow Hsong}",
year = "1999",
month = "10",
language = "English",
volume = "98",
pages = "678--682",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Tuberculous pleurisy with effusion

AU - Hsu, Chih Jen

AU - Bai, Kuan Jen

AU - Chiang, I. Hsin

AU - Wu, Ming Pin

AU - Lin, Tao Ping

AU - Kuo, Sow Hsong

PY - 1999/10

Y1 - 1999/10

N2 - To assess the clinical features of Taiwanese patients with tuberculous pleurisy and their response to treatment, we analyzed the records of patients treated for this condition from December 1990 through November 1995, at a regional 100-bed referral center for tuberculosis care. Diagnosis of tuberculous pleurisy was based on histologic evidence of caseating granulomatous inflammation in the pleural biopsy specimen, or evidence of mycobacteria in pleural fluid. Patients were also stratified on the basis of parenchymal involvement. Ninety-seven patients (79 men, 18 women) with a mean age of 47.5 (range, 15-90) years were included in the analysis. The two major symptoms were cough (69%) and shortness of breath (57%). Chest roentgenographs showed that the pleural effusion was unilateral in 88 (91%) patients, and small to moderate in amount in 74 (76%). Laboratory analysis of the pleural fluid showed moderate levels of glucose (4.6 mmol/L), with no significant difference between patients with and without parenchymal involvement. The levels of lactate dehydrogenase and triglycerides were significantly higher in patients with parenchymal involvement (172 vs 240.5 IU and 0.36 vs 0.45 mmol/L, respectively). In 85 of 93 patients (91%) with available data, lymphocytes were predominant in the differential count. All patients had received short-course chemotherapy for at least 6 months. After excluding the defaulters and patients receiving subsequent management in other hospitals, the overall rate of successful treatment was 97% (72/74). There was no significant difference in the treatment outcome between patients with parenchymal involvement and those without. None of the successfully treated patients had a relapse within a mean follow-up period of 31.7 ± 18.4 months. We conclude that current patients with tuberculous pleurisy in Taiwan are not young, and short-course chemotherapy with isoniazid, ethambutol, rifampicin, and pyrazinamide is an effective treatment. The presence of parenchymal tuberculous lesions does not appear to influence the treatment outcome.

AB - To assess the clinical features of Taiwanese patients with tuberculous pleurisy and their response to treatment, we analyzed the records of patients treated for this condition from December 1990 through November 1995, at a regional 100-bed referral center for tuberculosis care. Diagnosis of tuberculous pleurisy was based on histologic evidence of caseating granulomatous inflammation in the pleural biopsy specimen, or evidence of mycobacteria in pleural fluid. Patients were also stratified on the basis of parenchymal involvement. Ninety-seven patients (79 men, 18 women) with a mean age of 47.5 (range, 15-90) years were included in the analysis. The two major symptoms were cough (69%) and shortness of breath (57%). Chest roentgenographs showed that the pleural effusion was unilateral in 88 (91%) patients, and small to moderate in amount in 74 (76%). Laboratory analysis of the pleural fluid showed moderate levels of glucose (4.6 mmol/L), with no significant difference between patients with and without parenchymal involvement. The levels of lactate dehydrogenase and triglycerides were significantly higher in patients with parenchymal involvement (172 vs 240.5 IU and 0.36 vs 0.45 mmol/L, respectively). In 85 of 93 patients (91%) with available data, lymphocytes were predominant in the differential count. All patients had received short-course chemotherapy for at least 6 months. After excluding the defaulters and patients receiving subsequent management in other hospitals, the overall rate of successful treatment was 97% (72/74). There was no significant difference in the treatment outcome between patients with parenchymal involvement and those without. None of the successfully treated patients had a relapse within a mean follow-up period of 31.7 ± 18.4 months. We conclude that current patients with tuberculous pleurisy in Taiwan are not young, and short-course chemotherapy with isoniazid, ethambutol, rifampicin, and pyrazinamide is an effective treatment. The presence of parenchymal tuberculous lesions does not appear to influence the treatment outcome.

KW - Parenchymal involvement

KW - Treatment outcome

KW - Tuberculous pleurisy

UR - http://www.scopus.com/inward/record.url?scp=0032730840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032730840&partnerID=8YFLogxK

M3 - Article

VL - 98

SP - 678

EP - 682

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 10

ER -